Trial reportKidney international2019
Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
Trial report in Kidney international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.The Cochrane database of systematic reviews · 2024Pooled it
- A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial.Kidney360 · 2021Trial
- The creatinine conundrum in heart failure: rethinking AKI definitions.Intensive care medicine · 2026Article
- Management Strategies for Congestive Heart Failure in Chronic Kidney Disease: Narrative Review.Biomedicines · 2026Review
- Discontinuation of RAS Inhibition After an Acute Decline in Estimated Glomerular Filtration Rate.JAMA network open · 2026Article
- Protective association of renin-angiotensin system inhibitor use with skeletal muscle wasting in diabetic heart failure.Journal of diabetes investigation · 2026Article
- What to do with key cardiovascular drugs when kidney function worsens?Clinical kidney journal · 2026Review
- Low levels of adropin are associated with acute kidney injury after decongestion in patients with acutely decompensated heart failure.Journal of molecular and cellular cardiology plus · 2025Article
- Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?Heart failure clinics · 2024Review
- Pharmacological and Non-Pharmacological Advancements in Heart Failure Treatment.Reviews in cardiovascular medicine · 2024Review
- Management of Chronic Heart Failure in Dialysis Patients: A Challenging but Rewarding Path.Reviews in cardiovascular medicine · 2024Review
- An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease.Reviews in cardiovascular medicine · 2024Review
- Taboo in cardiology: renin-angiotensin-aldosterone system antagonists worsening renal failure.European heart journal supplements : journal of the European Society of Cardiology · 2024Article
- Assessment and management of heart failure in patients with chronic kidney disease.Heart failure reviews · 2024Review
- Designing acute kidney injury clinical trials.Nature reviews. Nephrology · 2024Review
- The effect of kidney function on guideline-directed medical therapy implementation and prognosis in heart failure with reduced ejection fraction.Clinical cardiology · 2024Article
- Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?Cardiology clinics · 2023Review
- Updates in Cardiorenal Syndrome.The Medical clinics of North America · 2023Review
- Challenges and Opportunities in Titrating Disease-Modifying Therapies in Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease.Current heart failure reports · 2023Review
- The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines.Journal of clinical medicine · 2022Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Angiotensin-converting enzyme inhibitors are beneficial in heart failure with reduced ejection fraction but are associated with acute declines in estimated glomerular filtration rate (eGFR). Prior studies evaluating thresholds of eGFR decline while using angiotensin-converting enzyme inhibitors in heart failure with reduced ejection have not taken into account this medication-driven decline. Here we used data from the Studies of Left Ventricular Dysfunction (SOLVD) trial of 6245 patients and performed Cox proportional hazards regression models to calculate hazard ratios of all-cause mortality and heart failure hospitalization-associated with percent eGFR decline at two- and six-weeks after randomization to enalapril versus placebo. In reference to placebo with equal degree of percent eGFR decline, any eGFR decline in the enalapril arm was associated with lower hazard of both outcomes. Under a conservative estimate using zero percent eGFR decline in the placebo arm as the reference, up to a 10% decline with enalapril was associated with mortality benefit (hazard ratio 0.87 [95% confidence interval 0.77, 0.99]) while up to a 35% decline was associated with decreased risk of heart failure hospitalization (0.78 [0.61, 0.98]). Under an intermediate estimate, up to a 15% decline with enalapril was associated with a mortality benefit (0.86 [0.77, 0.97]) and all levels of eGFR decline were associated with decreased risk of heart failure hospitalization. There was no percent eGFR decline, including up to 40%, in any models at either two- or six-weeks where enalapril was associated with higher mortality risk. Thus, in patients with reduced ejection fraction heart failure, enalapril is associated with decreased risk of mortality and heart failure hospitalizations. Hence, compelling reasons beyond moderate eGFR decline ought to be considered before its use is withdrawn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.